Pharmacological and structural understanding of the Trypanosoma cruzi proteasome provides key insights for developing site-specific inhibitors

Search results

• Finished

  Wellcome Centre for Anti-Infectives Research

  Baragana, B. (Investigator), Cook, S. (Investigator), De Rycker, M. (Investigator), Fairlamb, A. (Investigator), Ferguson, M. (Investigator), Field, M. (Investigator), Gilbert, I. (Investigator), Gray, D. (Investigator), Horn, D. (Investigator), Lee, M. (Investigator), Pawlowic, M. C. (Investigator), Read, K. (Investigator), Wyatt, P. (Investigator) & Wyllie, S. (Investigator)

  1/04/17 → 1/04/25

  Project: Research

  • Parasite 100%
  • Trypanosoma Cruzi 81%
  • Drug Discovery 78%
  • Trypanosoma Cruzi (T. cruzi) 64%
  • Chagas Disease 59%